The gist of it
Sarepta’s filed numbers tell a story of a company that briefly turned profitable in 2024, then swung back to a loss in 2025 after a year of safety crises and a failed confirmatory trial. Today the stock trades at roughly 1.2 times annual sales, a fraction of where it spent most of the past decade. The math says the business is priced as if the damage is permanent. The mood in the clinic, and in the pipeline, says the question is still open.
Two numbers that should not coexist
Sarepta Therapeutics generated $1.9 billion in revenue in fiscal year 2024, its first year of genuine profitability after a decade of losses. Its entire company today is valued at $2.4 billion. That means the market is pricing a business that once earned nearly two billion dollars in a single year at barely more than one year of those sales. For context, a corner bakery that grosses half a million a year and sells for six hundred thousand is priced the same way. Something went very wrong between then and now, and the filed numbers show exactly what.
How Sarepta got here
For most of its life, Sarepta was a company that spent far more than it earned. It built a franchise of exon-skipping drugs for Duchenne muscular dystrophy, a rare and devastating disease that robs boys of the ability to walk, then breathe. Exondys 51 came first, approved in 2016 under the FDA’s accelerated pathway, which lets a drug reach patients before a full clinical trial is complete, on the condition that a confirmatory study follows. Vyondys 53 and Amondys 45 followed the same route. Revenue climbed steadily, but so did losses, because the company kept reinvesting in a gene therapy it believed could do what the exon-skipping drugs could not: address the underlying disease rather than slow it.
That gene therapy, Elevidys, received accelerated FDA approval in June 2023 and its label was expanded to traditional approval in June 2024. The commercial launch drove revenue sharply higher in 2024, and for one year the math finally worked: a meaningful net profit, meaning real earnings for every dollar of sales. Investors celebrated. Then 2025 arrived.
In July 2025, following three patient deaths linked to acute liver failure, the FDA halted Elevidys shipments to non-ambulatory patients and paused related trials. By November, the drug carried a boxed warning, the FDA’s most serious safety label, and its approved use was narrowed. That same month, the Phase 3 ESSENCE confirmatory trial for Vyondys 53 and Amondys 45 failed its primary endpoint, meaning the studies that were supposed to prove those drugs worked did not deliver the required evidence. The stock fell roughly a third in a single pre-market session. The company laid off hundreds of people. The CEO announced his retirement.
That sequence, compressed into about five months, is why a business with more than two billion dollars in annual sales trades at barely more than two billion dollars today.
What the most recent filing actually shows
The 10-Q filed August 5, 2026, for the quarter ended June 30, is the freshest evidence. Total revenue for the second quarter of 2026 was $401 million, split between product sales and collaboration payments from partners. The gross margin, meaning what’s left of each revenue dollar after manufacturing costs, was about 63%, which is healthy for a pharmaceutical company. GAAP operating income, the profit from running the business before interest and taxes, was positive for the second consecutive quarter. That’s thin, but it marks a real trend.
The problem is the annual picture. The 10-K for fiscal year 2025 shows total revenue of $2.2 billion but a net loss of roughly $713 million, a net margin of approximately negative 32%. The swing from 2024’s profit to 2025’s loss reflects the Elevidys shipment halt and the costs of restructuring. The filed trend, then, is: a company that reached profitability, got knocked back, and is now rebuilding quarter by quarter.
The cash position as of June 30, 2026, was about $945 million, roughly equal to more than a year of the combined R&D and selling expense the company guided for 2026. That runway matters because Sarepta is still spending heavily on pipeline programs that have not yet generated revenue.
The conversation around the stock
The analyst community is split in ways that are unusually wide even for a biotech. MarketBeat reported on September 2, 2026, that individual price targets across roughly twenty analysts range from a deeply bearish single digits to a bullish high thirties, a spread of more than seven times from floor to ceiling. That is not a consensus; it is a disagreement about what kind of company Sarepta is.
Wolfe Research upgraded the stock to Outperform on July 9, 2026, citing pipeline optionality. Evercore’s Gavin Clark-Gartner held a neutral view as of August 10, and Barclays’ Eliana Merle held a similarly cautious target as of August 7. HC Wainwright persists with a deeply bearish view. Petri Dish Reports on Seeking Alpha, writing on August 28, 2026, put it plainly: the stock “looks optically like deep value,” but the market is “heavily discounting durability and risk.” That is a fair description of the tension.
New CEO Michael Severino, who took the role on July 28, 2026, said on the August 5 earnings call that the company expects “important data readouts in DM1 and FSHD” in the second half of 2026, referring to two additional rare muscle diseases where Sarepta is running early trials. Those readouts are the next hard evidence the market will weigh.
The math and the mood, side by side
Our data show Sarepta’s price-to-sales ratio, meaning what the market pays per dollar of annual revenue, sits at 1.2 times. The median for this company over the past decade is 11.7 times. A business that once commanded nearly twelve dollars of market value for every dollar of sales now commands barely one. That is the mood: the market has repriced Sarepta as a distressed asset, not a growth company.
The math from the filings is more complicated. Two consecutive quarters of operating profit, a strong gross margin, and nearly a billion dollars in cash suggest the business is not broken. But the narrowed 2026 product revenue guidance of $1.2 billion to $1.3 billion means the top line is contracting from its peak. Elevidys, which was once the engine of growth, is running at less than half the annual pace it once set. That is not a rounding error; it is a business that has materially shrunk from where it stood.
The supplemental applications for Amondys 45 and Vyondys 53, seeking conversion from accelerated to traditional approval, carry a PDUFA date, meaning an FDA decision deadline, of February 28, 2027. That decision will tell the market whether the exon-skipping franchise survives or shrinks further.
The filings show that the operating machinery is intact, the cash cushion is real, and the pipeline is active, but the revenue base has contracted sharply from its peak and the next chapter depends on clinical and regulatory outcomes that the filed numbers cannot predict, context investors can weigh against their own frameworks.
Reading the numbers
- $401 million, Q2 2026 total revenue (from the 10-Q filed August 5, 2026). What it is: the total money Sarepta collected in three months from drug sales and partner payments. What it means here: the quarterly run rate, annualized, implies roughly $1.6 billion in annual revenue, above the $1.2 to $1.3 billion product-only guidance, because the guidance excludes collaboration income. Example: a family business that grosses $400,000 in a quarter is running at $1.6 million a year, but if the owner says “product sales will be $1.2 to $1.3 million,” the rest is coming from a licensing deal with a neighbor, not the core shop.
- 63% gross margin, Q2 2026. What it is: for every dollar Sarepta collected, about 63 cents remained after paying to manufacture and deliver the drugs. What it means here: pharmaceutical margins at this level are competitive; the cost structure is not the problem. Example: a bakery that sells a loaf for $10 and spends $3.70 on flour, labor, and packaging keeps $6.30, a 63% gross margin.
- 1.2 times price-to-sales, versus a decade median of 11.7 times (our data). What it is: the price-to-sales ratio is the market value of the whole company divided by one year of revenue, a way to compare price to business size when earnings are unstable. What it means here: the market is paying roughly one-tenth of what it historically paid per dollar of Sarepta’s sales. Example: a house that used to sell for $1.17 million when the neighborhood earned $100,000 a year in rent is now listed at $120,000. The analogy illustrates two competing interpretations the market is pricing in: that the business has permanently shrunk, or that the repricing has moved beyond what the filed fundamentals alone would support, which of those reads is correct depends on outcomes the filings cannot yet resolve.
- $945 million cash position, June 30, 2026 (from the 10-Q filed August 5, 2026). What it is: the total of cash, equivalents, and short-term investments on hand. What it means here: at the guided $800 to $850 million in annual operating expenses, the company holds slightly more than one full year of spending in reserve. Example: a household earning $80,000 a year with $95,000 in savings is not in immediate danger, but it is not comfortable either.
Sources
- Sarepta 10-Q, quarter ended June 30, 2026 (SEC EDGAR)
- Sarepta 10-K, fiscal year ended December 31, 2025 (SEC EDGAR)
- Sarepta 10-K, fiscal year ended December 31, 2024 (SEC EDGAR)
- Sarepta Q2 2026 earnings call transcript, Motley Fool, August 12, 2026
- Sarepta 2026 revenue guidance, Seeking Alpha
- Petri Dish Reports, Seeking Alpha, August 28, 2026
- MarketBeat analyst targets, September 2, 2026
- FDA accelerated approval of Elevidys, June 2023
- FDA expanded approval of Elevidys, June 2024
- ESSENCE trial failure, Fierce Pharma
